Best of MS: AAN 2017

Chosen studies presented at AAN 2017 included an evaluation of cortical lesions in MS; 6-year outcomes of treatment with alemtuzumab in RRMS patients; an investigation of a possible link between viral infections, vitamin D deficiency, and pediatric-onset MS; and a look at the possibility of fatigue and lower limb problems predicting progression from RRMS to SPMS.